After three consecutive years of growth, total new premium for individual life combination products dropped 2% to $4.3 billion in 2018, according to LIMRA’s 2018 Individual Life Combination Products ...

The success of Boston Scientific's Taxus drug-eluting stent helped boost combination products' popularity. However, the regulatory requirements for such products are strict. Who Will Be the Lead ...

Packaging Extra Effort: Packaging for Combination Products Producing a suitable package for a combination product requires device companies to understand the regulations, materials, and processes ...

WINDSOR, Conn., Aug. 9, 2022 — Total new premium for individual life combination products increased 22% to $4.3 billion, compared with prior year results, and down slightly from the $4.8 billion in ...

Recently, the U.S. Food and Drug Administration’s (FDA’s) Office of Combination Products (OCP) published the final guidance “Principles of Premarket Pathways for Combination Products,” which provides ...

The U.S. Food and Drug Administration (FDA) recently finalized its guidance entitled “Requesting Food and Drug Administration Feedback on Combination Products,” stressing as it did in the draft ...

Developing a drug delivery device system (combination product) adds a layer of complexity to your pharmaceutical program that many companies underestimate until it's too late. Success depends not just ...

A new combination product comprising the triptan rizatriptan and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam has shown promising results in the treatment of migraine. In the phase 3 ...

Drug-device combination products—integrating therapeutic drugs with delivery devices such as insulin pens, autoinjectors, inhalers, wearable injectors, and drug-eluting stents—are becoming essential ...

Please provide your email address to receive an email when new articles are posted on . FDA recently approved Lybalvi for the treatment of schizophrenia and for use in manic and mixed (depressive and ...